nach oben

Erschienen in:

2013 | OriginalPaper | Buchkapitel

21. Infusionstherapie und Ernährung bei angeborenen Stoffwechselstörungen

verfasst von : Prof. Dr. E. Mönch

Erschienen in: Ernährungsmedizin Pädiatrie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Zahl der bekannten angeborenen Stoffwechselstörungen ist in den letzten Jahren auf mehr als 2.000 angestiegen. Bisher behandelbar sind davon aber nur etwa 200. Die hier zur Beschreibung getroffene Auswahl orientiert sich im Wesentlichen an den für das Neugeborenenscreening empfohlenen angeborenen Stoffwechselstörungen (Interdiziplinäre Screeningkommission der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin 2002). Statt der sehr seltenen und unterschiedlich zu therapierenden 3 Carnitin-Zyklus-Defekte, des LCHAD- und des VLCAD-Mangels („Differenzialdiagnostik“; ▶ Abschn. 21.5) wird der Ornithintranscarbamylasemangel (OTC-Mangel) exemplarisch für die Störungen in der Harnstoffsynthese und solche Erkrankungen abgehandelt, die mit schwerer Hyperammonämie einhergehen können.

Andresen BS, Bross P, Udvari S et al. (1997) The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? Hum Mol Genet 6: 695–707PubMedCrossRef

Arbeitsgemeinschaft für Pädiatrische Diätetik (APD) (2001) Nährwerttabelle für die Ernährung bei angeborenen Störungen des Aminosäurenstoffwechsels, 5. Aufl. Fa. SHS, Heilbronn

Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen (APS) (1997) Therapie von Patienten mit Phenylketonurie. Monatsschr Kinderheilkd 145: 961–962

Baumgartner ER, Suormala T, Wick H, Bausch J, Bonjour J-P (1985) Biotinidase deficiency: factors responsible for the increased biotin requirement. J Inherit Metab Dis 8 [Suppl 1]: 59–64PubMedCrossRef

Berry GT, Nissim I, Lin Z et al. (1995) Endogenous synthesis of galactose in normal men and patients with hereditary galactosemia. Lancet 346: 1073–1074PubMedCrossRef

Blau N (1996) The hyperphenylalaninemias. A differential diagnosis and international database of tetrahydrobiopterin deficiencies. Tectum, Marburg

Bremer HJ, Mönch E, Przyrembel H (1995) Eiweißzufuhr von Patienten mit Phenylketonurie. Monatsschr Kinderheilkd 143: 548–549

Brusilow SW, Horwich AL (2001) Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 1909–1963

Budd MA, Tanaka KR, Holmes LB et al. (1967) Isovaleric acidemia: clinical feature of a new genetic defect of leucine metabolism. N Engl J Med 277: 321–327PubMedCrossRef

Burlina AB, Ferrari V, Dionisi-Vici C et al. (1992) Allopurinol challenge test in children. J Inherit Metab Dis 15: 707–712PubMedCrossRef

Busquets C, Coll MJ, Christensen E et al. (1998) Feasibility of molecular prenatal diagnosis of glutaric aciduria type I in chorionic villi. J Inherit Metab Dis 21: 243–246PubMedCrossRef

Campbell AG, Rosenberg LE, Snodgrass PJ, Nuzum CT (1973) Ornithine transcarbamylase deficiency: a cause of lethal neonatal hyperammonemia in males. N Engl J Med 288: 1–6PubMedCrossRef

Carpenter K, Wiley V, Sim KG, Heath D, Wilcken B (2001) Evaluation of newborn child screening for medium chain acyl CoA dehydrogenase deficiency in 275,000 babies. Arch Dis Fetal Neonatal Ed 85: F105–109CrossRef

Carpenter KH, Potter M, Hammond JW, Wilcken B (1996) Benign persistent orotic aciduria and the possibility of misdiagnosis of OTC deficiency (abstract). J Inherit Metab Dis 19 [Suppl 1]: 1

Chuang DT, Shih VE (2001) Disorders of branched chain amino acid and keto acid metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 1971–2005

Clayton BE, Jenkins P, Round JM (1980) Pediatric chemical pathology – Clinical tests and reference range. Blackwell, Oxford [□ auch Dörner K (1990) Ausgewählte allgemeine Referenzwerte. In: Bachmann K-D, Ewerbeck W, Kleinhauer E, Rossi E, Stadler G (Hrsg) Pädiatrie in Praxis und Klinik, Bd. III. Fischer & Thieme, Stuttgart, S 1163 ff]

Cole H, Weremowicz S, Morton CC, Wolf B (1994) Localization of serum biotinidase (BTD) to human chromosome 3 in band p25. Genomics 22: 662–663PubMedCrossRef

Cowan MJ, Wara DW, Packman S et al. (1979) Multiple biotin-dependent carboxylase deficiencies associated with defects in T-cell and B-cell immunity. Lancet II: 115–118CrossRef

Divry P, David M, Gregersen N et al. (1983) Dicarboxylic aciduria due to medium chain acyl CoA dehydrogenase defect. A cause of hypoglycemia in childhood. Acta Paediatr Scand 72: 943–949PubMedCrossRef

Dixon AM, Leonard JV (1992) Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 67: 1387–1391PubMedCrossRef

Dyer CA, Kendler A, Philibotte T et al. (1996) Evidence for central nervous system glial cell plasticity in phenylketonuria. J Neuropathol Exp Neurol 55: 795–814PubMedCrossRef

Elsas LJ, Acosta PB (1999) Nutritional support of inherited metabolic disease. In: Shils ME, Olson JA, Shike M, Ross AC (eds) Modern nutrition in health and disease, 9th edn. Lea & Febiger, Philadelphia, pp 1003–1056

Elsas LJ, Lai K (1998) The molecular biology of galactosemia. Genet Med 1: 40–48PubMedCrossRef

Ensenauer R, Vockley J, Willard JM et al. (2004) A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 75:1136-1142PubMedCrossRef

Finkelstein JE, Hauser ER, Leonard CO, Brusilow SW (1990) Late onset ornithine transcarbamylase deficiency in male patients. J Pediatr 117: 897–902PubMedCrossRef

Francois B, Jaeken J, Gillis P (1990) Vigabatrin in the treatment of glutaric aciduria type I. J Inherit Metab Dis 13: 352–354PubMedCrossRef

Fujimoto A, Okano Y, Miyagi T, Isshiki G, Oura T (2000) Quantitative Beutler test for newborn mass screening of galactosemia using a fluorometric microplate reader. Clin Chem 46: 806–810PubMed

Gibson MK, Elpeleg ON, Wappner RS (1996) Disorders of leucine metabolism. In: Blau N, Duran M, Blaskovics M (eds) Physician’s guide to the laboratory diagnosis of metabolic diseases. Chapman & Hall, London, pp 125–144

Gitzelmann R (1995) Galactose-1-phosphate in the pathophysiology of galactosemia. Eur J Pediatr 154 [7 Suppl 2]: 45–49CrossRef

Gitzelmann R (2000) Disorders of galactose metabolism. In: Fernandes J, Saudubray J-M, Berghe G van den (eds) Inborn metabolic diseases, 3rd edn. Springer, Berlin Heidelberg New York, pp 103–109

Gitzelmann R, Arbenz UV, Willi UV (1992) Hypergalactosaemia and portosystemic encephalopathy due to persistence of ductus venosus Arantii. Eur J Pediatr 151: 564–568PubMedCrossRef

Goodman SI, Frerman FE (1995) Organic acidemias due to defect in lysine oxidation: 2-keto-adipic acidemia and glutaric acidemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 7th edn. McGraw-Hill, New York, pp 1451–1460

Goodman SI, Markey SP, Moe PG, Miles BS, Teng CC (1975) Glutaric aciduria: a „new“ disorder of amino acid metabolism. Biochem Med 12: 12–21PubMedCrossRef

Gouyon JB, Semama D, Prevot A, Desgres J (1996) Removal of branched-chain amino acids and alpha-ketoisocaproate by haemofiltration and haemodiafiltration. J Inherit Metab Dis 19: 610–620PubMedCrossRef

Greene P (1992) Baclofen in the treatment of dystonia. Clin Neuropharmacol 15: 276–288PubMedCrossRef

Griffiths P, Ward N, Harvie A, Cockburn F (1998) Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. J Inherit Metab Dis 21:29–38PubMedCrossRef

Haworth JC, Booth FA, Chudley AE et al. (1991) Phenotypic variability in glutaric aciduria type I: report of fourteen cases in five Canadian Indian kindreds. J Pediatr 118: 52–58PubMedCrossRef

Hilliges C, Awiszus D, Wendel U (1993) Intellectual performance of children with maple syrup urine disease. Eur J Pediatr 152: 144–147PubMedCrossRef

Hoffmann GF, Zschocke J (1999) Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis 22: 381–391PubMedCrossRef

Hoffmann GF, Böhles HJ, Burlina A et al. (1995) Early signs and course of disease of glutaryl CoA dehydrogenase deficiency. J Inherit Metab Dis 18: 173–176PubMedCrossRef

Hoffmann GF, Athanassopoulos S, Burlina AB et al. (1996) Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. Neuropediatrics 27: 115–123PubMedCrossRef

Holton JB, Walter JH, Tyfield LA (2001) Galactosemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 1553–1587

Hommes FA (1989) The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninemia. J Inherit Metab Dis 12: 41–46PubMedCrossRef

Iafolla AK, Thompson RJ, Roe CR (1994) Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 124: 409–415PubMedCrossRef

Interdiziplinäre Screeningkommission der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin (2002) Richtlinien zur Organisation und Durchführung des Neugeborenenscreenings auf angeborene Stoffwechselstörungen und Endokrinopathien in Deutschland. Monatsschr Kinderheilkd 150:1424–1440CrossRef

Item C, Hagerty BP, Mühl A et al. (2002) Mutations at the galactose-1-p-uridyltransferase gene in infants with a positive galactosemia newborn screening test. Pediatr Res 51: 511–516PubMedCrossRef

Itoh T, Ito T, Ohba S et al. (1996) Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose. Tohoku J Exp Med 179: 101–109PubMedCrossRef

Jakobs C, Schweitzer S, Dorland B (1995) Galactitol in galactosemia. Eur J Pediatr 154 [7 Suppl 2]: 50–52CrossRef

Kure S, Hou D-C, Ohura T et al. (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135: 375–378PubMedCrossRef

Kyllerman M, Skjeldal OH, Lundberg M et al. (1994) Dystonia and dyskinesia in glutaric aciduria type I: clinical heterogeneity and therapeutic considerations. Mov Disord 9: 22–30PubMedCrossRef

Lehotay DC, Page J le, Thompson JR, Rockman-Greenberg C (2004) Blood acylcarnitine levels in normal newborns and heterozygotes for medium-chain acyl-CoA dehydrogenase deficiency: a relationship between genotype and biochemical phenotype? J Inherit Metab Dis 27: 81–88PubMedCrossRef

Leonard JV (2000) Disorders of the urea cycle. In: Fernandes J, Saudubray JM, Berghe G van den (eds) Inborn metabolic diseases. Diagnosis and treatment, 3rd edn. Springer, Berlin Heidelberg New York, pp 215–222

Levy HL, Sepe SJ, Shih VE, Vawter GF, Klein JO (1977) Sepsis due to Escherichia coli in neonates with galactosemia. N Engl J Med 297: 823–825PubMedCrossRef

Lipkin PH, Roe CR, Goodman SI, Batshaw ML (1988) A case of glutaric acidemia type I: effect of riboflavin and carnitine. J Pediatr 112: 62–65PubMedCrossRef

Lou HC, Güttler F, Lykkelund C, Bruhn P, Niederwieser A (1985) Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur J Pediatr 144: 17–20PubMedCrossRef

Lynch BC, Pitt DB, Maddison TG, Wraith JE, Danks DM (1988) Maternal phenylketonuria: successful outcome in four pregnancies treated prior to conception. Eur J Pediatr 148: 72–75PubMedCrossRef

Maestri NE, Brusilow SW, Clissold DB, Banett SS (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335: 855–859PubMedCrossRef

Medical Research Council Working Party on Phenylketonuria (1993) Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. BMJ 306: 115–119CrossRef

Menkes JH, Hurst BL, Craig JM (1954) A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 14: 462–467PubMed

Mönch E, Link R (2006) Diagnostik und Therapie bei angeborenen Stoffwechselstörungen. 2te erweiterte Auflage. SPS, Heilbronn. ISBN 3-936145-26-1

Mönch E, Hoffmann GF, Przyrembel H, Colombo J-P, Wermuth B (1998) Diagnose und Behandlung des Ornithintranscarbamylase (OTC)-Mangels. Monatsschr Kinderheilkd 146: 652–658CrossRef

Moslinger D, Muhl A, Suormala T, Baumgartner R, Stoeckler-Ipsiroglu S (2003) Molecular characterisation and neuropsychological outcome of 21 patients with profound biotinidase deficiency detected by newborn screening and family studies. Eur J Pediatr 162 [Suppl 1]: 46–49CrossRef

Muntau AC, Röschinger W, Pfluger T, Enders A, Hoffmann GF (1977) Subdurale Hygrome und Hämatome im Säuglingsalter als Initialmanifestation der Glutarazidurie Typ 1. Monatsschr Kinderheilkd 145: 646–651CrossRef

Muntau AC, Röschinger W, Habich M et al. (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 347: 2122–2132PubMedCrossRef

Müting D (1988) Behandlung chronisch Leberkranker mit Laktulose und Bifidum-Milch. Grundlagen und Probleme. Fortschr Med 106: 369–372PubMed

Naylor EW, Chace DH (1999) Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 14 [Suppl 1]: S4–8PubMed

Newman JD, Ramsden CA, Balazs ND (2002) Monitoring neonatal hypoglycemia with the Accu-chek advantage II glucose meter: the cautionary tale of galactosemia. Clin Chem 48: 2071PubMed

Ono H, Mawatari H, Mizoguchi N, Eguchi T, Sakura N (1998) Clinical features and outcome of eight infants with intrahepatic porto-venous shunts detected in neonatal screening for galactosaemia. Acta Paediatr 87: 631–634PubMedCrossRef

Palmieri M, Mazur A, Berry GT et al. (1999) Urine and plasma galactitol in patients with galactose-1-phosphate uridyltransferase deficiency galactosemia. Metabolism 48: 1294–1302PubMedCrossRef

Pelet A, Rotig A, Bonaiti-Pellie C et al. (1990) Carrier detection in a partially dominant x-linked disease: ornithine transcarbamylase deficiency. Hum Genet 84: 167–171PubMedCrossRef

Platt LD, Koch R, Azen C et al. (1992) Maternal phenylketonuria collaborative study, obstetric aspects and outcome: the first 6 years. Am J Obstet Gynecol 166: 1150–1160PubMed

Podskarbi T (2001) Molekulargenetik des Phenylalaninhydroxylase-Mangels (PAH) In: Zabransky S (Hrsg) Screening auf angeborene endokrine und metabole Störungen. Springer, Wien, S 216–217CrossRef

Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K (2001) Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 358: 1063–1064PubMedCrossRef

Przyrembel H (1984) Diättherapie bei Glykogenose, Laktose- und Fruktoseintoleranz, Galaktosämie aus der Sicht des Arztes. Ernaehr Umschau 31 (Sonderheft): 137–143

Rashed MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res 38: 324–331PubMedCrossRef

Rhead WJ, Tanaka K (1980) Demonstration of a specific mitochondrial isovaleryl-CoA dehydrogenase deficiency in fibroblasts from patients with isovaleric acidemia. Proc Natl Acad Sci U S A 77: 580–583PubMedCrossRef

Roe C, Ding J (2001) Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2297–2326

Rohr FJ, Doherty LB, Waisbren ES et al. (1987) New England maternal PKU project: prospective study of untreated and treated pregnancies and their outcomes. J Pediatr 110: 391–398PubMedCrossRef

Schweitzer S, Shin Y, Jakobs C, Brodehl J (1993) Long-term outcome in 134 patients with galactosemia. Eur J Pediatr 152: 36–43PubMedCrossRef

Scriver CR, Kaufman S (2001) The hyperphenylalaninemia. Phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited diseases, 8th edn. McGraw-Hill, New York, pp 1667–1724

Scriver CR, Clow CL, George H (1985) So-called thiamine-responsive maple syrup urine disease: 15-years follow-up of the original patient. J Pediatr 107: 763–765PubMedCrossRef

Scriver CR, Kaufman S, Eisensmith RC, Woo SLC (1995) The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited diseases, 7th edn. McGraw-Hill, New York, pp 1015–1075

Sidbury JB, Smith EK, Harlan W (1967) An inborn error of short-chain fatty acid metabolism: the odor-of-sweaty-feet syndrome. J Pediatr 70: 8–15PubMedCrossRef

Stanley C (2000) Disorders of fatty acid oxidation. In: Fernandez J, Saudubray JM, Berghe G van den (eds) Inborn metabolic disease. Springer, Berlin Heidelberg New York, pp 139–150

Sweetman L (1991) Organic acid analysis. In: Hommes FA (ed) Techniques in diagnostic human biochemical genetics. Wiley-Liss, New York, pp 143–176

Sweetman L, Nyhan WL (1986) Inheritable biotin-treatable disorders and associated phenomena. Annu Rev Nutr 6: 317–343PubMedCrossRef

Sweetman L, Williams JC (2001) Branched chain organic acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2125–2163

Vockley J, Ensenauer R (2006) Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet. 142C:95-103PubMedCrossRef

Waggoner DD, Buist NR, Donnell GN (1990) Long-term prognosis in galactosemia: results of a survey of 350 cases. J Inherit Metab Dis 13: 802–818PubMedCrossRef

Wallace SJ (1985) Biotinidase deficiency: presymptomatic treatment. Arch Dis Child 60: 574–575PubMedCrossRef

Wang S, Fernhoff PM, Khoury M (2000) Is the G985A allelic variant of medium-chain acyl-CoA dehydrogenase a risk factor for sudden infant death syndrome? A pooled analysis. Pediatrics 105: 1175–1176PubMedCrossRef

Wendel U, Bakkeren J, Jong J de, Bongaerts G (1995) Glutaric aciduria mediated by gut bacteria. J Inherit Metab Dis 18: 358–359PubMedCrossRef

Wilcken B, Hammond J, Silink M (1994) Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 70: 410–412PubMedCrossRef

Wimmer K (2002) Diätetik bei Galaktosämie. In: Grotzke M, Müller E (Hrsg) Klinik und Behandlung angeborener Störungen im Kohlenhydrat- und Energie-Stoffwechsel in der Pädiatrie. SPS, Heilbronn, S 72–75

Wolf B (2001) Disorders of biotin metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3935–3962

Wolf B, Grier RE, Secor McVoy JR, Heard GS (1985) Biotinidase deficiency: a novel vitamin recycling defect. J Inherit Metab Dis 8 [Suppl 1]: 53–58PubMed

Titel: Infusionstherapie und Ernährung bei angeborenen Stoffwechselstörungen
verfasst von: Prof. Dr. E. Mönch
Verlag: Springer Berlin Heidelberg
Buch: Ernährungsmedizin Pädiatrie
Print ISBN: 978-3-642-29816-5

Electronic ISBN: 978-3-642-29817-2

Copyright-Jahr: 2013
DOI: https://doi.org/10.1007/978-3-642-29817-2_21

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

21. Infusionstherapie und Ernährung bei angeborenen Stoffwechselstörungen

Zusammenfassung

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie